{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:56:10Z","timestamp":1782143770611,"version":"3.54.5"},"reference-count":32,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:00:00Z","timestamp":1565222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Understanding antibiotic allergies and the risk of cross-sensitivity between and within antibiotic classes can have a substantial impact on patient care. The purpose of this review article is to provide insight into carbapenem allergies, describing the overall incidence, risk factors, and in-class cross-sensitivity. A PubMed search was conducted using the following search terms: carbapenem, allergy, cross-sensitivity, incidence, imipenem\/cilastatin, meropenem, ertapenem, and doripenem. Article bibliographies and relevant drug monographs were also reviewed. The overall reported incidence of carbapenem allergy is 0.3%\u20133.7%. Risk of cross-sensitivity between penicillins and carbapenems is less than 1% in patients with a positive penicillin skin test. Data on cross-sensitivity between cephalosporins and carbapenems are limited; however, the risk appears to also be low. No clinical studies have described cross-sensitivity between the carbapenem agents thus far. The limited data available from case reports demonstrates a lack of cross-sensitivity between the individual carbapenems, suggesting that an alternative carbapenem may cautiously be used in patients with a reported carbapenem allergy.<\/jats:p>","DOI":"10.3390\/pharmacy7030110","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T11:05:32Z","timestamp":1565262332000},"page":"110","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Overview and Insights into Carbapenem Allergy"],"prefix":"10.3390","volume":"7","author":[{"given":"Yuman","family":"Lee","sequence":"first","affiliation":[{"name":"College of Pharmacy and Health Sciences, St. John\u2019s University, Queens, NY 11439, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Bradley","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Health Sciences, St. John\u2019s University, Queens, NY 11439, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,8,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Henry, R. (2019). Etymologia: Carbapenem. Emerg. Infect. Dis., 25, Available online: https:\/\/wwwnc.cdc.gov\/eid\/article\/25\/7\/et-2507_article.","DOI":"10.3201\/eid2507.ET2507"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenem Past Present and Future","volume":"55","author":"Endimiani","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_3","unstructured":"(2019, June 05). Primaxin (Imipenem\/Cilastatin) [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/050587s074lbl.pdf."},{"key":"ref_4","unstructured":"(2019, June 05). Merrem (Meropenem) [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/050706s037lbl.pdf."},{"key":"ref_5","unstructured":"(2019, June 05). Invanz (Ertapenem) [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021337s038lbl.pdf."},{"key":"ref_6","unstructured":"(2019, June 05). Doribax (Doripenem) [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022106s008lbl.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1177\/0897190014546109","article-title":"Beta-lactam hypersensitivity and cross-reactivity","volume":"27","author":"Terico","year":"2014","journal-title":"J. Pharm. Pract."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/jac\/18.Supplement_E.193","article-title":"The safety profile of imipenem\/cilastatin: Worldwide clinical experience based on 3470 patients","volume":"18","author":"Calandra","year":"1986","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/j.1552-4604.1988.tb05735.x","article-title":"The efficacy results and safety profile of imipenem\/cilastatin from the clinical research trials","volume":"28","author":"Calandra","year":"1988","journal-title":"J. Clin. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2165\/00002018-200730080-00002","article-title":"Safety profile of meropenem: An updated review of over 6,000 patients treated with meropenem","volume":"30","author":"Linden","year":"2007","journal-title":"Drug Saf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"ii75","DOI":"10.1093\/jac\/dkh209","article-title":"Safety and tolerability of ertapenem","volume":"53","author":"Teppler","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1086\/599813","article-title":"Safety of intravenous infusion of doripenem","volume":"49","author":"Redman","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/cea.12468","article-title":"Standards of Care Committee of the British Society for Allergy and Clinical Immunology. Management of allergy to penicillins and other beta-lactams","volume":"45","author":"Mirakian","year":"2015","journal-title":"Clin. Exp. Allergy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"778.e1","DOI":"10.1016\/j.amjmed.2009.01.034","article-title":"Self-reported antibiotic allergy incidence and prevalence: Age and sex effects","volume":"122","author":"Macy","year":"2009","journal-title":"Am. J. Med."},{"key":"ref_15","first-page":"159","article-title":"Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock","volume":"38","author":"Idsoe","year":"1968","journal-title":"Bull. World Health Org."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0091-6749(84)90108-8","article-title":"Risk factors for drug allergy","volume":"74","author":"Adkinson","year":"1984","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF02914542","article-title":"Drug allergy in cystic fibrosis","volume":"9","author":"Moss","year":"1991","journal-title":"Clin. Rev. Allergy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"354.e11","DOI":"10.1016\/j.amjmed.2005.10.052","article-title":"Is there cross-reactivity between penicillins and cephalosporins?","volume":"119","author":"Apter","year":"2006","journal-title":"Am. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jaci.2008.03.037","article-title":"Clinical and genetic risk factors of self-reported penicillin allergy","volume":"122","author":"Apter","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0091-6749(91)91632-4","article-title":"Familial drug allergy","volume":"87","author":"Attaway","year":"1991","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0091-6749(88)91001-9","article-title":"Imipenem cross-reactivity with penicillin in humans","volume":"82","author":"Saxon","year":"1988","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1345\/aph.1L486","article-title":"Allergic cross-sensitivity between penicillin, carbapenem, and monobactam antibiotics: What are the chances?","volume":"43","author":"Frumin","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1086\/382880","article-title":"Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy","volume":"38","author":"Prescott","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/cid\/ciu587","article-title":"A systematic review: Can one prescribe carbapenems to patients with IgE-mediated allergy to penicillins or cephalosporins?","volume":"59","author":"Kula","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jaci.2014.10.011","article-title":"Tolerability of aztreonam and carbapenems in patients with IgE-mediated hypersensitivity to penicillins","volume":"135","author":"Gaeta","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jaci.2010.06.052","article-title":"IgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and tolerability of penicillins, monobactams, and carbapenems","volume":"126","author":"Romano","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_27","first-page":"251","article-title":"Antigenicity tests of meropenem (English summary)","volume":"40","author":"Nakanishi","year":"1992","journal-title":"Chemotherapy (Tokyo)"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1034\/j.1398-9995.2000.00360.x","article-title":"IgE-mediated anaphy-lactic reaction to imipenem","volume":"55","author":"Chen","year":"2000","journal-title":"Allergy"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2003.10.055","article-title":"Peters\/Lack of cross-reactivity to meropenem in a patient with an allergy to imipenem-cilastatin","volume":"113","author":"Seth","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1592\/phco.27.9.1334","article-title":"Safe Use of Meropenem in a Patient with a Possible Nonimmediate Allergy to Imipenem","volume":"27","year":"2007","journal-title":"Pharmacotherapy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jaip.2014.06.015","article-title":"Cross-reactivity between carbapenems: Two case reports","volume":"2","author":"Lezcano","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.jaip.2019.01.052","article-title":"Anaphylactic shock to meropenem with ertapenem tolerance: A case report","volume":"7","author":"Cardona","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/7\/3\/110\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:09:32Z","timestamp":1760188172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/7\/3\/110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,8]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["pharmacy7030110"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy7030110","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,8]]}}}